Resources

Showing 73 Results

The Certainty of Uncertainty in Health Technology Assessment 

A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.

NPC in Chain Drug Review: Fostering a More Informed Drug Pricing Conversation

To kick off the new year, NPC's John M. O’Brien writes in Chain Drug Review about the need for a more informed public discussion about the role that prescription drugs play in our health care system…

NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients

In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…

Drug Spending Mirrors Spending on Other Health Care Services

Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are disregarding…

Health Care Stakeholders Can Learn from Pharmacists’ Patient-Centered Perspective

In a commentary for Pharmacy Times, NPC's John M. O’Brien describes the commitment of pharmacists to ensuring patient access to needed medicines and says other health care stakeholders should follow…

Reference Pricing Isn’t Worth the Risk to Innovation and Patient Health

A Health Affairs Blog co-authored by NPC's Michael Ciarametaro explores the tradeoffs and risks associated with international reference pricing and suggests alternative policy approaches that would…

At the Heart of It: How Innovation Drives Improved Patient Outcomes

In honor of World Heart Day, NPC looks at how innovative medical interventions have vastly improved cardiovascular disease outcomes.

Avoiding Methodological Faults in Real-World Evidence

Researchers from Brigham and Women’s Hospital, Harvard Medical Center and NPC found that the potential for biased findings in RWE studies increases substantially in the absence of a rigorous and…

Chain Drug Review Commentary by John O'Brien, Don't Limit Innovation

Working Together to Deliver Innovation for Patients During COVID-19 and Beyond

What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.

Morning Consult Commentary on Biopharmaceutical Price Regulation, from July 30, 2020

NPC in Morning Consult: Biopharmaceutical Price Regulation - No Panacea for Patients

In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.

Illustrated image of hepatitis cell - yellow with blue interior with other cells floating in background

On World Hepatitis Day, Looking at Innovation That Goes Beyond a Pill

Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…

The Trade-off for Price Controls: Are We Willing to Accept Fewer Medicines?

It's possible to strike a balance between innovation and efficient spending, and to implement policies ensuring that resources are being invested in treatments, procedures and public health efforts…

Focus on Whole Person Quality Care When Implementing Budget Caps

The National Pharmaceutical Council hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…

AMCP Partnership Forum: Preparing for and Managing Rare Diseases

Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…

U.S. vs. EU: Not a Direct Comparison When It Comes to Drug Pricing

It’s challenging to compare U.S. and ex-U.S. countries’ drug prices and health spending, given the big differences in the countries’ economies, health care systems, payment mechanisms and disease…

What’s In Your RWE Evaluation Toolbox?

Real-world evidence (RWE) – information collected from everyday health care experiences – is growing in availability, and many health care decision-makers are interested in understanding and using…

Online Tools to Synthesize Real-World Evidence of Comparative Effectiveness Research to Enhance Formulary Decision Making

The authors describe and compare the features and characteristics of five tools to evaluate real-world evidence studies and add clarity on what the tools provide.

Filter by: